Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)

Oral semaglutide has potent anti-hyperglycemic efficacy in phase III trials. However, the complicated dosing instructions hamper to use this drug; therefore, we evaluated the efficacy and safety of oral semaglutide in subjects with type 2 diabetes in a real-world clinical setting. In this multi-cent...

Full description

Saved in:
Bibliographic Details
Main Authors: Sho Furusawa, Hiroshi Nomoto, Chiho Oba-Yamamoto, Jun Takeuchi, Miki Ito, Hiroyoshi Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Tatsuya Atsumi
Format: Article
Language:English
Published: The Japan Endocrine Society 2024-06-01
Series:Endocrine Journal
Subjects:
Online Access:https://www.jstage.jst.go.jp/article/endocrj/71/6/71_EJ23-0648/_html/-char/en
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832591896134811648
author Sho Furusawa
Hiroshi Nomoto
Chiho Oba-Yamamoto
Jun Takeuchi
Miki Ito
Hiroyoshi Kurihara
Shin Aoki
Aika Miya
Hiraku Kameda
Akinobu Nakamura
Tatsuya Atsumi
author_facet Sho Furusawa
Hiroshi Nomoto
Chiho Oba-Yamamoto
Jun Takeuchi
Miki Ito
Hiroyoshi Kurihara
Shin Aoki
Aika Miya
Hiraku Kameda
Akinobu Nakamura
Tatsuya Atsumi
author_sort Sho Furusawa
collection DOAJ
description Oral semaglutide has potent anti-hyperglycemic efficacy in phase III trials. However, the complicated dosing instructions hamper to use this drug; therefore, we evaluated the efficacy and safety of oral semaglutide in subjects with type 2 diabetes in a real-world clinical setting. In this multi-center retrospective observational study, we analyzed subjects with type 2 diabetes newly treated with an oral semaglutide for >6 months at four medical centers located in Sapporo, Japan. The changes in glycated hemoglobin, body weight, and other metabolic parameters were evaluated and any adverse event leading to semaglutide discontinuation were recorded from February 2021 to December 2022. This study was registered with the University Hospital Medical Information Network Center (UMIN000050583). Of 543 subjects who met the inclusion criteria, data for 434 subjects (age 55.5 ± 12.6 years; body mass index 29.6 ± 6.0 kg/m2) were analyzed. After a 6 months of observation period, semaglutide 3 mg, 7 mg, or 14 mg was used by 55 (12.7%), 241 (55.5%), and 138 (31.8%) of subjects, respectively. Both glycated hemoglobin and body weight significantly improved: 7.65 ± 1.11% to 6.88 ± 0.91% (p < 0.001) and 80.2 ± 19.2 kg to 77.6 ± 19.2 kg (p < 0.001), respectively. Efficacy was also confirmed in the subgroup switched from other anti-hyperglycemic agents, including dipeptidyl peptidase-4 inhibitors. In total, 154 subjects had symptomatic gastrointestinal symptoms and 39 (7.2%) were discontinued semaglutide due to the adverse events. None of the participants experienced severe hypoglycemic events. Oral semaglutide in subjects with type 2 diabetes improved glycemic control and body weight in a real-world clinical setting.
format Article
id doaj-art-248049dd9a5c4e8c94aa8491ee12b524
institution Kabale University
issn 1348-4540
language English
publishDate 2024-06-01
publisher The Japan Endocrine Society
record_format Article
series Endocrine Journal
spelling doaj-art-248049dd9a5c4e8c94aa8491ee12b5242025-01-22T05:07:43ZengThe Japan Endocrine SocietyEndocrine Journal1348-45402024-06-0171660361610.1507/endocrj.EJ23-0648endocrjReal-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)Sho Furusawa0Hiroshi Nomoto1Chiho Oba-Yamamoto2Jun Takeuchi3Miki Ito4Hiroyoshi Kurihara5Shin Aoki6Aika Miya7Hiraku Kameda8Akinobu Nakamura9Tatsuya Atsumi10Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, JapanSapporo Diabetes and Thyroid Clinic, Sapporo 060-0807, JapanSapporo Diabetes and Thyroid Clinic, Sapporo 060-0807, JapanKurihara Clinic, Sapporo 004-0053, JapanKurihara Clinic, Sapporo 004-0053, JapanAoki Clinic, Sapporo 003-0023, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, JapanOral semaglutide has potent anti-hyperglycemic efficacy in phase III trials. However, the complicated dosing instructions hamper to use this drug; therefore, we evaluated the efficacy and safety of oral semaglutide in subjects with type 2 diabetes in a real-world clinical setting. In this multi-center retrospective observational study, we analyzed subjects with type 2 diabetes newly treated with an oral semaglutide for >6 months at four medical centers located in Sapporo, Japan. The changes in glycated hemoglobin, body weight, and other metabolic parameters were evaluated and any adverse event leading to semaglutide discontinuation were recorded from February 2021 to December 2022. This study was registered with the University Hospital Medical Information Network Center (UMIN000050583). Of 543 subjects who met the inclusion criteria, data for 434 subjects (age 55.5 ± 12.6 years; body mass index 29.6 ± 6.0 kg/m2) were analyzed. After a 6 months of observation period, semaglutide 3 mg, 7 mg, or 14 mg was used by 55 (12.7%), 241 (55.5%), and 138 (31.8%) of subjects, respectively. Both glycated hemoglobin and body weight significantly improved: 7.65 ± 1.11% to 6.88 ± 0.91% (p < 0.001) and 80.2 ± 19.2 kg to 77.6 ± 19.2 kg (p < 0.001), respectively. Efficacy was also confirmed in the subgroup switched from other anti-hyperglycemic agents, including dipeptidyl peptidase-4 inhibitors. In total, 154 subjects had symptomatic gastrointestinal symptoms and 39 (7.2%) were discontinued semaglutide due to the adverse events. None of the participants experienced severe hypoglycemic events. Oral semaglutide in subjects with type 2 diabetes improved glycemic control and body weight in a real-world clinical setting.https://www.jstage.jst.go.jp/article/endocrj/71/6/71_EJ23-0648/_html/-char/enclinical trialglucagon-like peptide-1 receptor agonistglycemic controltype 2 diabetes
spellingShingle Sho Furusawa
Hiroshi Nomoto
Chiho Oba-Yamamoto
Jun Takeuchi
Miki Ito
Hiroyoshi Kurihara
Shin Aoki
Aika Miya
Hiraku Kameda
Akinobu Nakamura
Tatsuya Atsumi
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
Endocrine Journal
clinical trial
glucagon-like peptide-1 receptor agonist
glycemic control
type 2 diabetes
title Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
title_full Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
title_fullStr Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
title_full_unstemmed Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
title_short Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
title_sort real world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes a multicenter retrospective observational study the sapporo oral sema study
topic clinical trial
glucagon-like peptide-1 receptor agonist
glycemic control
type 2 diabetes
url https://www.jstage.jst.go.jp/article/endocrj/71/6/71_EJ23-0648/_html/-char/en
work_keys_str_mv AT shofurusawa realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy
AT hiroshinomoto realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy
AT chihoobayamamoto realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy
AT juntakeuchi realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy
AT mikiito realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy
AT hiroyoshikurihara realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy
AT shinaoki realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy
AT aikamiya realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy
AT hirakukameda realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy
AT akinobunakamura realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy
AT tatsuyaatsumi realworldclinicalevidenceoforalsemaglutideonmetabolicabnormalitiesinsubjectswithtype2diabetesamulticenterretrospectiveobservationalstudythesapporooralsemastudy